Search results
Showing 736 to 750 of 9039 results
All NICE products on self-harm. Includes any guidance and quality standards.
This webpage covers NICE guidelines on breast cancer. The table below presents the guidelines alphabetically with links to the surveillance report...
This quality standard covers the diagnosis and initial management of ectopic pregnancy and miscarriage in women, trans men and non-binary people in their first trimester (up to 13 completed weeks of pregnancy). It includes assessment and diagnosis for people with suspected early pregnancy loss. It describes high-quality care in priority areas for improvement.
View quality statements for QS69Show all sections
Sections for QS69
- Quality statements
- Quality statement 1: Timely referral to early pregnancy assessment services
- Quality statement 2: Ultrasound to identify miscarriage or tubal ectopic pregnancy
- Quality statement 3: Confirming a diagnosis of miscarriage
- Quality statement 4: Anti-D immunoglobulin prophylaxis (up to and including 11+6 weeks of pregnancy)
- Update information
- About this quality standard
All NICE products on infectious disease prevention and control. Includes any guidance, advice and quality standards.
All NICE products on artificial intelligence. Includes any guidance and advice.
All NICE products on complications of cancer. Includes any guidance, advice and quality standards.
All NICE products on eating disorders. Includes any guidance and quality standards.
This webpage covers all NICE's guidelines on cardiometabolic disease prevention and treatment The table presents the guidelines alphabetically within...
This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.
View quality statements for QS180Show all sections
Sections for QS180
- Quality statements
- Quality statement 1: Referral – chronic open angle glaucoma and related conditions
- Quality statement 2: Referral for cataract surgery
- Quality statement 3: Treatment – late age-related macular degeneration (wet active)
- Quality statement 4: Monitoring late age-related macular degeneration (wet active)
- Quality statement 5: Reassessment – chronic open angle glaucoma or related conditions
- Quality statement 6: Certificate of vision impairment
- Update information
In development Reference number: GID-TA11804 Expected publication date: 15 July 2026
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)
NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA867
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA879
NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA910
NICE is unable to make a recommendation on esketamine (Spravato) for treating major depressive disorder in adults at imminent risk of suicide because Janssen did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA899
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)
NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA901